Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
07 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
01 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
22 sept. 2022 07h00 HE
|
Revolution Medicines, Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to...
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
01 sept. 2022 16h05 HE
|
Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
Revolution Medicines to Participate in Upcoming Investor Conferences
31 août 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
09 août 2022 16h02 HE
|
Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
28 juil. 2022 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
22 juil. 2022 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
19 juil. 2022 22h41 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
19 juil. 2022 16h01 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...